Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Provided By GlobeNewswire
Last update: Jan 27, 2025
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® -
Read more at globenewswire.comNASDAQ:DRTSW (5/27/2025, 8:16:35 PM)
0.25
+0 (+0.04%)
NASDAQ:DRTS (5/29/2025, 11:24:21 AM)
3.05
+0.07 (+2.35%)
Find more stocks in the Stock Screener
